



THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

Personalized risk stratification through attribute matching for clinical decision making in clinical conditions with aspecific symptoms: the example of syncope

Citation for published version:

Solbiati, M, Quinn, JV, Dipaola, F, Duca, P, Furlan, R, Montano, N, Reed, MJ, Sheldon, RS, Sun, BC, Ungar, A, Casazza, G & Costantino, G 2020, 'Personalized risk stratification through attribute matching for clinical decision making in clinical conditions with aspecific symptoms: the example of syncope', *PLoS ONE*, vol. 15, no. 3, pp. e0228725. <https://doi.org/10.1371/journal.pone.0228725>

Digital Object Identifier (DOI):

[10.1371/journal.pone.0228725](https://doi.org/10.1371/journal.pone.0228725)

Link:

[Link to publication record in Edinburgh Research Explorer](#)

Document Version:

Peer reviewed version

Published In:

PLoS ONE

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.



1 **Personalized risk stratification through attribute**
2 **matching for clinical decision making in clinical**
3 **conditions with aspecific symptoms: the example of**
4 **syncope**

5
6 Monica Solbiati¹, James V. Quinn², Franca Dipaola³, Piergiorgio Duca⁴, Raffaello Furlan⁵,
7 Nicola Montano⁶, Matthew J. Reed⁷, Robert S. Sheldon⁸, Benjamin C. Sun⁹, Andrea
8 Ungar¹⁰, Giovanni Casazza^{11,*}, Giorgio Costantino¹², on behalf of the SYNERGI
9 (SYNcope Expert Research Group International)[^].

10
11 ¹ UOC Pronto Soccorso e Medicina d'Urgenza, Fondazione IRCCS Ca' Granda, Ospedale
12 Maggiore Policlinico, and Dipartimento di Scienze Cliniche e di Comunità, Università
13 degli Studi di Milano, Milan, Italy, monica.solbiati@gmail.com.

14 ² Department of Emergency Medicine, Stanford University, Stanford, CA, USA,
15 quinnj@stanford.edu.

16 ³ Internal Medicine, Humanitas Research Hospital, Humanitas University, Rozzano, Italy,
17 franca.dipaola@humanitas.it.

18 ⁴ Dipartimento di Scienze Biomediche e Cliniche "L. Sacco", Università degli Studi di
19 Milano, Milan, Italy, piergiorgio.duca@unimi.it.

20 ⁵ Internal Medicine, Humanitas Research Hospital, Humanitas University, Rozzano, Italy,
21 raffaello.furlan@hunimed.eu.

22 ⁶ Dipartimento di Medicina Interna, Fondazione IRCCS Ca' Granda, Ospedale Maggiore
23 Policlinico, and Dipartimento di Scienze Cliniche e di Comunità, Università degli Studi di
24 Milano, Milan, Italy, nicola.montano@unimi.it.

25 ⁷ Emergency Medicine Research Group Edinburgh (EMERGE), Royal Infirmary of
26 Edinburgh, and Edinburgh Acute Care, Usher Institute of Population Health Sciences and
27 Informatics, University of Edinburgh, Edinburgh, UK,
28 Matthew.Reed@nhslothian.scot.nhs.uk.

29 ⁸ Libin Cardiovascular Institute of Alberta, University of Calgary, Calgary, Canada,
30 sheldon@ucalgary.ca.

31 ⁹ Department of Emergency Medicine, Center for Policy Research-Emergency Medicine,
32 Oregon Health and Science University, Portland, OR, USA, sunb@ohsu.edu.

33 ¹⁰ S.O.D. Geriatria e Terapia Intensiva Geriatrica, AOU Careggi e Università degli Studi di
34 Firenze, Florence, Italy, andrea.ungar@unifi.it.

35 ¹¹ Dipartimento di Scienze Biomediche e Cliniche "L. Sacco", Università degli Studi di
36 Milano, Milan, Italy, giovanni.casazza@unimi.it.

37 ¹² UOC Pronto Soccorso e Medicina d'Urgenza, Fondazione IRCCS Ca' Granda, Ospedale
38 Maggiore Policlinico, and Dipartimento di Scienze Cliniche e di Comunità, Università
39 degli Studi di Milano, Milan, Italy, giorgic2@gmail.com.

40

41 * Corresponding author: giovanni.casazza@unimi.it; Tel.: +39 02.50319653.

42 ^Membership of the SYNcope Expert Research Group International is provided in the
43 Acknowledgments.

44 **Abstract**

45 Background: Risk stratification is challenging in conditions, such as chest pain,
46 shortness of breath and syncope, which can be the manifestation of many possible
47 underlying diseases. In these cases, decision tools are unlikely to accurately identify all the
48 different adverse events related to the possible etiologies. Attribute matching is a prediction
49 method that matches an individual patient to a group of previously observed patients with
50 identical characteristics and known outcome. We used syncope as a paradigm of clinical
51 conditions presenting with aspecific symptoms to test the attribute matching method for the
52 prediction of the personalized risk of adverse events. Methods: We selected the 8 predictor
53 variables common to the individual-patient dataset of 5 prospective emergency department
54 studies enrolling 3388 syncope patients. We calculated all possible combinations and the
55 number of patients in each combination. We compared the predictive accuracy of attribute
56 matching and logistic regression. We then classified ten random patients according to
57 clinical judgment and attribute matching. Results: Attribute matching provided 253 of the
58 384 possible combinations in the dataset. Twelve (4.7%), 35 (13.8%), 50 (19.8%) and 160
59 (63.2%) combinations had a match size ≥ 50 , ≥ 30 , ≥ 20 and < 10 patients, respectively. The
60 AUC for the attribute matching and the multivariate model were 0.59 and 0.74, respectively.
61 Conclusions: Attribute matching is a promising tool for personalized and flexible risk
62 prediction. Large databases will need to be used in future studies to test and apply the
63 method in different conditions.

64 **Keywords:** syncope; attribute matching; risk; prediction; personalized; emergency.

65

66 **Introduction**

67 Clinical decision tools (CDT) combine different predictors (from patients' history,
68 clinical examination and tests results) to assess the probability of a diagnosis, prognosis, or

69 response to treatment of an individual patient [1]. The statistical techniques used in this
70 process are usually based on multivariate models such as logistic regression [2]. Other
71 approaches include recursive partitioning analysis and artificial neural networks [3–5]. As
72 they are based on models, CDTs are able to predict the risk of any hypothetical patient, even
73 those with a combination of risk factors different from all the patients of the derivation
74 cohort. Therefore, we do not know how the CDT will perform in subjects with specific
75 clinical presentations or needs. Indeed, they lack the ability to provide personalized
76 estimates as required in the era of precision medicine. For example, patients with
77 uncommon diseases are likely not to be correctly risk stratified by CDTs. In addition, the
78 risk estimates of composite outcomes that are usually provided by CDTs cannot always be
79 applied to all patients, as the definition of “acceptable risk” depends on the patient at risk.
80 Hence the need to assess a personalized risk rather than providing a simple binary answer
81 [6].

82 Moreover, risk stratification is challenging in conditions (as chest pain, shortness of
83 breath and syncope) presenting with aspecific symptoms that can be the manifestation of
84 many possible underlying diseases. In these cases, decision tools are unlikely to accurately
85 identify all the different adverse events related to the possible etiologies. In syncope, which
86 is a paradigm of the above conditions, the traditionally derived risk stratification tools have
87 failed in predicting adverse events [7–12]. Here, an individualized risk assessment would
88 allow an estimate of not only the probability of a composite endpoint, but rather a detailed
89 risk profile that provides the individual risk of each specific outcome (e.g. arrhythmia or
90 pulmonary embolism).

91 Attribute matching (AM) is a prediction approach that differs considerably from the
92 regression models and has shown promising results in ruling out acute coronary syndrome
93 and pulmonary embolism in patients with chest pain [13–15]. Instead of considering each
94 clinical characteristic as an individual predictor and deriving a risk estimate based on the

95 sum of their regression coefficients, each individual patient is matched to a group of patients
96 with the same combination of the relevant clinical characteristics (or attributes) from a large
97 reference database. Therefore, each patient is matched to a group of patients with identical
98 risk profile and known outcomes. This approach results in a proportion (i.e. the number
99 patients who had the outcome of interest on the number of previously studied matched
100 patients) that provides the probability (with confidence interval) of the single adverse event.
101 This process resembles the definition of pre-test probability by an expert clinician, which,
102 having seen many patients who had similar clinical characteristics as the patient under
103 consideration, could provide an estimate of the probability of something bad happening. In
104 this case, the computer does so with less variability and without the clinician having to be
105 experienced nor an expert. The aim of this study was to explore the use of AM to predict the
106 personalized risk of adverse events and to compare it to multivariate logistic regression to
107 analyze the possible similarities, differences, strengths and weaknesses of the two methods
108 using syncope in the Emergency Department (ED) as an example.

109

110 **Materials and Methods**

111 To apply AM in a large database, we used an individual-patient dataset from a previous
112 international collaboration that involved 3388 patients prospectively included in 5 studies
113 enrolling syncope patients in the ED from 2000 to 2014 [8,16–20]. The dataset was
114 analyzed to detect demographic and clinical variables among those considered to be
115 relevant for syncope risk stratification as have shown to be related to adverse events
116 [16,17,19,21]. Each single dataset was re-analyzed to create homogeneously defined
117 variables for abnormal electrocardiogram (ECG) and 7-10 day serious outcomes [7,12,22].
118 We finally identified the variables that were available in all 5 datasets.

119 The AM estimates of the probability of serious adverse is based upon computer
120 assisted, database-derived system. The clinician puts in a predefined set of clinical attributes
121 for a subject for whom the probability of a serious outcome is unknown. A computer
122 program queries a large patient database, and returns only the patients who share the
123 identical attribute profile as the patient under consideration. The proportion of these
124 attribute-matched subjects who had a clinical outcome of interest is the probability of
125 adverse events.

126 According to the “Standardized reporting guidelines for emergency department
127 syncope risk-stratification research” serious outcomes included any of the following [22]:
128 1) all-cause and syncope-related death, 2) ventricular fibrillation, 3) sustained and
129 symptomatic non-sustained ventricular tachycardia, 4) sinus arrest with cardiac pause > 3 s,
130 5) sick sinus syndrome with alternating bradycardia and tachycardia, 6) second-degree type
131 2 or third-degree AV block, 7) permanent pacemaker (PM) or implantable cardioverter
132 defibrillator (ICD) malfunction with cardiac pauses, 8) aortic stenosis with valve area ≤ 1
133 cm^2 , 9) hypertrophic cardiomyopathy with outflow tract obstruction, 10) left atrial myxoma
134 or thrombus with outflow tract obstruction, 11) myocardial infarction, 12) pulmonary
135 embolism, 13) aortic dissection, 14) occult hemorrhage or anemia requiring transfusion, 15)
136 syncope or fall resulting in major traumatic injury (requiring admission or
137 procedural/surgical intervention), 16) PM or ICD implantation, 17) cardiopulmonary
138 resuscitation, 18) syncope recurrence with hospital admission, and 19) cerebrovascular
139 events.

140 To explore the potential application of AM in this context, we calculated 1) all the
141 unique combinations of the selected variables (or attributes); 2) the number of combinations
142 verified in at least one patient in the database; 3) the number of combinations with a match
143 size ≥ 50 , ≥ 30 , ≥ 20 and < 10 patients.

144 The potential predictors of short-term severe outcomes were first individually
145 evaluated and then analyzed by multivariate logistic regression analysis with a stepwise
146 selection strategy. In case of one predictor was missing in one patient, it was considered as
147 absent.

148 The overall diagnostic performance of both multivariate logistic regression and AM was
149 assessed with Receiver Operating Characteristics (ROC) curves and their area under the curve
150 (AUC). To exemplify how the AM would work in the real world, we considered 10 random
151 patients who presented with syncope, as defined according to the main international
152 guidelines and consensus papers [11,12], to the ED of Fondazione IRCCS Ca' Granda,
153 Ospedale Maggiore Policlinico, Milano from September 2015 to February 2017 [23]. For
154 each patient we recorded the presence or absence of any of the above attributes and
155 calculated the risk of adverse events according to the AM approach. For this purpose we
156 paired the patient of interest to the patients with an identical combination of attributes in the
157 database and calculated the probability of adverse events as the percentage of the matched
158 previously studied patients who had the outcome of interest [13]. A 95% confidence interval
159 (CI) was constructed using the binomial distribution. As part of a larger study on syncope
160 ED risk stratification, we asked the ED physician to assess the patient's risk of short-term
161 adverse events (low, intermediate or high) according to his/her clinical judgement.

162 The data for this study were collected and analyzed anonymously. The 10 patients in
163 Table 4 had given written informed to have their data collected and the Internal Review
164 Board of L. Sacco Hospital (approval number 608/2015) had approved their use for this
165 study purpose. IRB approval was obtained by the single primary study authors.

166 Analyses were performed using the SAS (release 9.4) statistical software.

167

168 **Results**

169 The main characteristics of the 3388 patients included in the individual-patient
 170 database are reported in Table 1. We identified 8 common predictors: sex, age (considered
 171 as a 3-level categorical variable: < 45 year, \geq 45 and < 65 years, \geq 65 years), trauma
 172 following syncope, presence of abnormal ECG, history of cerebrovascular disease, history
 173 of cardiac disease, history of syncope and absence of prodrome.

174 **Table 1. Characteristics of the included patients.**

Variables	EGSYS [18,24]	SFSR [19]	STePS [16]	ROSE [17]	Sun 2007 [20]	Total
Total number of patients	465	684	695	1067	477	3388
Age, median (IQR)	70 (45-81)	70 (42-81)	64 (41-78)	69 (48-81)	58 (35-79)	67 (43-80)
N of admitted patients (%)	178 (38)	364 (53)	265 (38)	538 (50)	286 (60)	1631 (48)
N of men (%)	253 (54)	281 (41)	306 (44)	480 (45)	210 (44)	1530 (45)
N of patients with history of syncope (%)	195 (42)	124 (18)	389 (56)	176 (16)	160/45 7 (34)	1044/2 931 (36)
N of patients without prodrome (%)	122 (26)	260 (38)	195 (28)	410 (38)	141 (30)	1128 (33)
N of patients with trauma following syncope (%)	133 (29)	45 (7)	162 (23)	316 (30)	n.a.	656/29 11 (23)
N of patients with abnormal ECG (%)	178 (38)	222 (32)	202 (29)	665 (62)	170 (36)	1437 (42)
N of patients with a history of cardiovascular disease (%)	153 (33)	139 (20)	178 (26)	284 (27)	150 (31)	904 (27)
N of patients with a history of cerebrovascular disease (%)	166 (36)	115 (17)	227 (33)	n.a.	169 (35)	677/23 21 (29)
N of patients with serious outcomes at 10 days (%)*	93 (20)	81 (12)	44 (6)	49 (5)	62 (13)	329 (10)
N of deaths	6	6	7	6	1	26 (1)
N of arrhythmias	31	30		20	32	
N of cardiopulmonary resuscitations			5	2		

N of myocardial infarctions	6	33		1
N of structural cardiopulmonary diseases	9	10	14	6
N of PM insertions or malfunctions	43		25	11
N of ICD insertions or malfunctions	5		2	2
N of haemorrhages		24	7	8

175 IQR: interquartile range; ECG: electrocardiogram; PM: pacemaker; ICD: Implantable
176 Cardioverter Defibrillator; n.a.: not available. *Some patients had more than one outcome.

177 The AM method provided 253 of the 384 possible combinations. No patient in the
178 database matched the remaining 131 combinations of predictors. Only 12 of the 253 (4.7%)
179 combinations had a match size ≥ 50 patients, 35 (13.8%) had a match size ≥ 30 patients, 50
180 (19.8%) had a match size ≥ 20 patients, and most (160, 63.2%) had a match size < 10
181 patients.

182 At univariate analysis, the risk factors significantly associated with severe short-term
183 outcomes were age, male gender, syncope during exertion, abnormal ECG, history of
184 cardiovascular disease, history of cerebrovascular disease, absence of prodrome, and
185 history of arterial hypertension (Table 2).

186 **Table 2. Risk factors for severe short-term outcomes within 10 days (univariate**
187 **analysis)**

	Severe Outcomes		p-value*
	Yes (%) (n=329)	No (%) (n=3059)	
Male gender, n (%)	196 (60)	1334 (44)	<0.0001
Age, n (%)			<0.0001
< 45 years	24 (7)	869 (28)	
≥ 45 and < 65 years	56 (17)	658 (22)	
≥ 65 years	249 (76)	1532 (50)	
Syncope during exertion, n (%)	31 (9)	187 (6)	0.0211
Trauma following syncope, n (%)	64 (19)	592 (19)	0.9651
Abnormal ECG, n (%)	229 (70)	1208 (39)	<0.0001
Medical history, n (%)			
Cardiovascular disease	161 (49)	743 (24)	<0.0001
Cerebrovascular disease	132 (40)	545 (18)	<0.0001
Arterial hypertension	154 (47)	1104 (36)	0.0001
Previous syncope	109 (33)	964 (31)	0.5491
Absence of prodrome, n (%)	126 (38)	1002 (33)	0.0430

*Chi-square test; ECG: electrocardiogram

188 At multivariate analysis, male gender, age between 45 and 65 years, age over 65 years,
189 an abnormal ECG, and a past medical history of cerebrovascular disease were independent
190 risk factors for the development of severe adverse outcomes in the short term (Table 3).

191 **Table 3. Risk factors for severe short-term outcomes within 10 days at logistic**
192 **multivariate regression (stepwise selection)**

	Adjusted Odds Ratio	95% Confidence Interval	p-value*
Male gender	1.6	1.3 – 2.0	0.0001
Age			<0.0001
< 45 years	1.0		
≥ 45 and < 65 years	2.3	1.4 – 3.8	
≥ 65 years	3.5	2.3 – 5.5	
Abnormal ECG	2.6	2.0 – 3.3	<0.0001
Medical history of cerebrovascular disease	1.9	1.5 – 2.5	<0.0001

*Chi-square test; ECG: electrocardiogram

193 The AUC for the AM and the multivariate model were 0.59 and 0.74, respectively.

194 The predicted probabilities for each of the 10 patients, together with the ED physician's
195 perceived risk are reported in Table 4. To note, none of these patients had an adverse event
196 at 7-30 days of follow-up according to standardized criteria [22]. The detailed case
197 description of the 10 patients is reported in S1 Table.

198 **Table 4. Predicted probabilities according to attribute matching and clinical**
199 **judgement in the 10 example patients.**

Case n	Attribute matching		ED physician
	patients at risk*	10-day SAE, % (95% CI)	
1	15	20 (7-45)	High risk
2	70	4 (1-12)	Intermediate risk
3	42	5 (1-16)	Intermediate risk
4	12	0 (0-24)	Intermediate risk
5	84	4 (1-10)	Intermediate risk
6	34	6 (2-19)	Low risk
7	42	5 (1-16)	High risk
8	6	16 (3-56)	High risk
9	6	0 (0-39)	High risk
10	3	33 (6-79)	High risk

200 ED: Emergency Department; SAE: serious adverse events; *: number of patients with the
201 same combination of risk factors; CI: Confidence Interval.

202

203 **Discussion**

204 In this paper, to assess the potential value of AM and to compare it to multivariate
205 logistic regression we used syncope as a paradigm of those conditions, such as chest pain
206 and shortness of breath, in which the creation of accurate CDTs is particularly challenging.
207 If the condition under consideration is the manifestation of many possible underlying
208 diseases, CDTs are unlikely to accurately identify all the different adverse events related to
209 the possible etiologies [25]. In syncope, CDTs are usually designed to identify multiple
210 diagnoses (i.e. pulmonary embolism, aortic dissection, high grade atrioventricular block)
211 and adverse events that might be related to a high number of conditions (i.e. bleeding
212 requiring transfusion, trauma, pacemaker implant). To increase complexity, the reference
213 standard for diagnosis is sometimes missing.

214 This study explores a method to estimate the probability of serious adverse events
215 based on AM. This approach allows the clinician to determine the probability of a serious
216 outcome of a patient based on the presence of predefined risk predictors (or attributes). This
217 patient is matched to all patients with the same combination of attributes included in a large
218 reference database. The proportion of these attribute-matched patients who had the outcome
219 of interest represents the estimate, with its 95% confidence interval, of the probability that
220 such outcome might occur in the patient under consideration [15]. This process resembles
221 the definition of pre-test probability by an expert clinician, which, having seen many
222 patients who had similar clinical characteristics as the patient under consideration, could
223 provide an estimate of the probability of something bad happening. In this case the
224 computer does so with less variability and without the clinician having to be experienced
225 nor an expert.

226 The inclusion of a large number of attributes would result in very specific and detailed
227 clinical risk profiles at a cost of requiring a very large reference database. In the present

228 work, we used an eight-attribute profile and a 3388-patient database. Among the 384
229 possible combinations, only 12 had a match size ≥ 50 patients and most had a match size < 10
230 patients. Therefore, our data do not offer a clinically useful prediction tool at this stage and
231 the AUC shows that logistic regression is superior if derived from the dataset we used, but
232 this method seems promising, as it has some advantages as compared to model-derived
233 clinical decision tools. Indeed, the successful use of a model to predict the probability of a
234 serious outcome requires that the results are reproduced in an external validation so that
235 both the external validity and robustness of the model are verified. Moreover, models
236 require that the predictors are assigned a weight that allow to estimate the risk of adverse
237 events in every patient, also in those that had no matching subject in the derivation database
238 (for example for patients that have a rare condition). Attribute matching differs from scoring
239 systems derived from logistic regression, which use predictor variables expressed by an
240 individual patient under consideration to guide that patient into a predefined category that
241 predicts a probability. This outcome probability is estimated from knowledge (i.e., the
242 magnitude of importance of predictor variables) manifested by the patients that were used to
243 construct the model. On the other hand, attribute matching works in reverse fashion. Instead
244 of placing the patient under consideration into a category, the computer program finds the
245 patients from a reference database who “look like” the patient insofar as they are identical
246 on the binary predictor variables. Therefore, the risk of patients with an uncommon
247 combination of predictors, might not be able at all to find a match in the derivation dataset.
248 However, being aware that the patient’s estimated probability might be based on very
249 limited evidence, will allow both the clinician and the patient to take a decision conscious
250 that it might be based on uncertainty, rather than deciding on the false confidence provided
251 by models.

252 Several thousands of subjects need to be enrolled for acceptable AM risk prediction. If this
253 was the case, only administrative databases could be used to use AM for risk prediction. In
254 the era of big data and with the increase in the availability and accuracy of population-based
255 databases, this might not be a barrier to the use of AM for risk prediction in several
256 conditions [26].

257 AM has several advantages: 1) The possibility to have as output not only the probability
258 of a composite serious outcome, but a detailed patient specific risk profile based on the
259 probability of different outcomes allowing for a more personalized decision making. Also,
260 the possibility to make the risk profile explicit and more personalized could allow for more
261 meaningful shared decision making with the patient; 2) as there is no need for model fitting,
262 patients could be always added to the dataset thus increasing the probability estimate
263 precision; 3) the flexibility of AM would allow to consider different predictors in different
264 patients, thus allowing an individualized estimate; 4) as there is no statistical modelling, the
265 reliability of the results is based on the similarity between the population of the reference
266 database and every-day patients rather than on complex statistical calculations; 5) the
267 prediction tools based on models, such as logistic regression and neural networks provide a
268 risk estimate in every case, also in patients whose combination of clinical characteristics are
269 different from each patient's combination in the derivation cohort, giving the physician a
270 false confidence. Conversely, AM would allow both the clinician and the patient to make a
271 decision being aware that it might be based on uncertainty, rather than deciding on the false
272 confidence provided by models. This is crucial in the perspective of a modern medicine
273 increasingly based on personalized and shared decision making.

274 AM has also some important limitations: 1) to be used in clinical practice the reference
275 database should include a large number of patients; 2) the choice of predictors is crucial for
276 the successful application of the method; 3) AM will promote personalized medicine,

277 providing the probability of events, rather than a clear indication of what to do (i.e. admit vs
278 discharge). However, the need to interpret and apply the estimated probability to the context
279 may be felt as a limitation due to lack of certainty; 4) a score is easy to remember and apply,
280 while AM requires data collection and computer input ideally through a
281 computer/smartphone app. Furthermore, the value of CDT as early and necessary work to
282 determine the choice of predictors to be considered should not be underestimated as they
283 help determine what attributes and factors should be collected and used for AM.

284 Some limitations of the present study should be acknowledged. The database we used
285 was collected for different purposes and, although we did our best to homogenize the data,
286 we could not overcome some heterogeneity among the single studies' dataset. Also, we used
287 as predictors the eight variables in common between the original datasets with no *a priori*
288 decision on the number of predictors to be selected. However, this number strongly
289 influences the sample size of the population to be included in the AM database.
290 Nonetheless, it must be pointed out that syncope and this database were used only as a
291 working example to show the possible applications of AM.

292

293 **Conclusions**

294 In conclusion, our study shows that the AM is a promising method to predict the risk of
295 adverse events in clinical practice and could offer some advantages as compared with
296 standard methods based on logistic regression. However, large datasets are required to
297 obtain a precise and informative estimate. Future studies should explore the use of
298 administrative databased or big data in conditions in which there is less clinical
299 heterogeneity to use AM and to compare it with the traditional risk stratification tools.

300

301 **Funding:** This research received no external funding.

302 **Conflicts of Interest:** The authors declare no conflict of interest.

303

304 **Acknowledgments**

305 Members of the SYNcope Expert Research Group International (SYNERGI):

306 - Franca Barbic: Internal Medicine, Humanitas Research Hospital, Humanitas
307 University, Rozzano, Italy

308 - Giovanni Casazza: Dipartimento di Scienze Biomediche e Cliniche "L. Sacco",
309 Università degli Studi di Milano, Milan, Italy

310 - Giorgio Costantino (lead author): UOC Pronto Soccorso e Medicina d'Urgenza,
311 Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, and Dipartimento di
312 Scienze Cliniche e di Comunità, Università degli Studi di Milano, Milan, Italy,
313 giorgic2@gmail.com

314 - Franca Dipaola: Internal Medicine, Humanitas Research Hospital, Humanitas
315 University, Rozzano, Italy

316 - Raffaello Furlan: Internal Medicine, Humanitas Research Hospital, Humanitas
317 University, Rozzano, Italy

318 - Rose A Kenny: Department of Medical Gerontology, Trinity College, Dublin, Ireland

319 - James V Quinn: Department of Emergency Medicine, Stanford University, Stanford,
320 CA, USA

321 - Satish R Raj: Libin Cardiovascular Institute of Alberta, University of Calgary,
322 Calgary, Canada

323 - Matthew J Reed: Emergency Medicine Research Group Edinburgh (EMERGE),
324 Royal Infirmary of Edinburgh, and Edinburgh Acute Care, Usher Institute of
325 Population Health Sciences and Informatics, University of Edinburgh, Edinburgh,
326 UK

- 327 - Robert S Sheldon: Libin Cardiovascular Institute of Alberta, University of Calgary,
328 Calgary, Canada
- 329 - Win-Kuang Shen: Department of Cardiovascular Medicine, Mayo Clinic, Phoenix,
330 AZ, USA
- 331 - Monica Solbiati: UOC Pronto Soccorso e Medicina d'Urgenza, Fondazione IRCCS
332 Ca' Granda, Ospedale Maggiore Policlinico, and Dipartimento di Scienze Cliniche e
333 di Comunità, Università degli Studi di Milano, Milan, Italy
- 334 - Benjamin C. Sun: Department of Emergency Medicine, Center for Policy
335 Research-Emergency Medicine, Oregon Health and Science University, Portland,
336 OR, USA
- 337 - Venkatesh Thiruganasambandamoorthy: Department of Emergency Medicine,
338 University of Ottawa, Ottawa, ON, Canada

339

340 **References**

- 341 1. McGinn, T.G.; Guyatt, G.H.; Wyer, P.C.; Naylor, C.D.; Stiell, I.G.; Richardson, W.S.;
342 for the Evidence-Based Medicine Working Group Users' Guides to the Medical
343 Literature. *JAMA* **2000**, *284*, 79.
- 344 2. Guyatt, G.; Walter, S.; Shannon, H.; Cook, D.; Jaeschke, R.; Heddle, N. Basic
345 statistics for clinicians: 4. Correlation and regression. *CMAJ* **1995**, *152*, 497–504.
- 346 3. Rudy, T.E.; Kubinski, J.A.; Boston, J.R. Multivariate analysis and repeated
347 measurements: A primer. *J. Crit. Care* **1992**, *7*, 30–41.
- 348 4. Cook, E.F.; Goldman, L. Empiric comparison of multivariate analytic techniques:
349 advantages and disadvantages of recursive partitioning analysis. *J. Chronic Dis.* **1984**,

- 350 37, 721–31.
- 351 5. Baxt, W.. Application of artificial neural networks to clinical medicine. *Lancet* **1995**,
352 346, 1135–1138.
- 353 6. Lilford, R.J.; Pauker, S.G.; Braunholtz, D.A.; Chard, J. Decision analysis and the
354 implementation of research findings. *BMJ* **1998**, 317, 405–9.
- 355 7. Costantino, G.; Sun, B.C.; Barbic, F.; Bossi, I.; Casazza, G.; Dipaola, F.; McDermott,
356 D.; Quinn, J.; Reed, M.J.; Sheldon, R.S.; et al. Syncope clinical management in the
357 emergency department: a consensus from the first international workshop on syncope
358 risk stratification in the emergency department. *Eur. Heart J.* **2016**, 37, 1493–8.
- 359 8. Costantino, G.; Casazza, G.; Reed, M.; Bossi, I.; Sun, B.; Del Rosso, A.; Ungar, A.;
360 Grossman, S.; D’Ascenzo, F.; Quinn, J.; et al. Syncope risk stratification tools vs
361 clinical judgment: an individual patient data meta-analysis. *Am. J. Med.* **2014**, 127,
362 1126.e13–25.
- 363 9. Costantino, G.; Solbiati, M.; Casazza, G.; Bonzi, M.; Vago, T.; Montano, N.;
364 McDermott, D.; Quinn, J.; Furlan, R. Usefulness of N-Terminal Pro-B-Type
365 Natriuretic Peptide Increase as a Marker for Cardiac Arrhythmia in Patients With
366 Syncope. *Am. J. Cardiol.* **2014**, 113, 98–102.
- 367 10. Solbiati, M.; Sheldon, R.S. Implantable rhythm devices in the management of
368 vasovagal syncope. *Auton. Neurosci.* **2014**, 184, 33–39.
- 369 11. Brignole, M.; Moya, A.; de Lange, F.J.; Deharo, J.-C.; Elliott, P.M.; Fanciulli, A.;
370 Fedorowski, A.; Furlan, R.; Kenny, R.A.; Martín, A.; et al. 2018 ESC Guidelines for
371 the diagnosis and management of syncope. *Eur. Heart J.* **2018**, 39, 1883–1948.

- 372 12. Sun, B.C.; Costantino, G.; Barbic, F.; Bossi, I.; Casazza, G.; Dipaola, F.; McDermott,
373 D.; Quinn, J.; Reed, M.; Sheldon, R.S.; et al. Priorities for Emergency Department
374 Syncope Research. *Ann. Emerg. Med.* **2014**, *64*, 649-655.e2.
- 375 13. Kline, J.A.; Courtney, D.M.; Than, M.P.; Hogg, K.; Miller, C.D.; Johnson, C.L.;
376 Smithline, H.A. Accuracy of very low pretest probability estimates for pulmonary
377 embolism using the method of attribute matching compared with the wells score.
378 *Acad. Emerg. Med.* **2010**, *17*, 133–141.
- 379 14. Kline, J.A.; Stubblefield, W.B. Clinician gestalt estimate of pretest probability for
380 acute coronary syndrome and pulmonary embolism in patients with chest pain and
381 dyspnea. *Ann. Emerg. Med.* **2014**, *63*, 275–280.
- 382 15. Kline, J.A.; Johnson, C.L.; Pollack, C. V; Diercks, D.B.; Hollander, J.E.; Newgard,
383 C.D.; Garvey, J.L. Pretest probability assessment derived from attribute matching.
384 *BMC Med. Inform. Decis. Mak.* **2005**, *5*, 26.
- 385 16. Costantino, G.; Perego, F.; Dipaola, F.; Borella, M.; Galli, A.; Cantoni, G.; Dell’Orto,
386 S.; Dassi, S.; Filardo, N.; Duca, P.G.; et al. Short- and long-term prognosis of syncope,
387 risk factors, and role of hospital admission: results from the STePS (Short-Term
388 Prognosis of Syncope) study. *J. Am. Coll. Cardiol.* **2008**, *51*, 276–83.
- 389 17. Reed, M.J.; Newby, D.E.; Coull, A.J.; Prescott, R.J.; Jacques, K.G.; Gray, A.J. The
390 ROSE (Risk Stratification of Syncope in the Emergency Department) Study. *J. Am.*
391 *Coll. Cardiol.* **2010**, *55*, 713–721.
- 392 18. Del Rosso, A.; Ungar, A.; Maggi, R.; Giada, F.; Petix, N.R.; De, S.T.; Menozzi, C.;
393 Brignole, M. Clinical predictors of cardiac syncope at initial evaluation in patients

- 394 referred urgently to a general hospital: the EGSYS score. *Heart* **2008**, *94*, 1620–1626.
- 395 19. Quinn, J. V; Stiell, I.G.; McDermott, D.A.; Sellers, K.L.; Kohn, M.A.; Wells, G.A.
396 Derivation of the San Francisco Syncope Rule to predict patients with short-term
397 serious outcomes. *Ann. Emerg. Med.* **2004**, *43*, 224–32.
- 398 20. Sun, B.C.; Mangione, C.M.; Merchant, G.; Weiss, T.; Shlamovitz, G.Z.; Zargaraff, G.;
399 Shiraga, S.; Hoffman, J.R.; Mower, W.R. External validation of the San Francisco
400 Syncope Rule. *Ann. Emerg. Med.* **2007**, *49*, 420–7, 427.e1–4.
- 401 21. Colivicchi, F.; Ammirati, F.; Melina, D.; Guido, V.; Imperoli, G.; Santini, M.
402 Development and prospective validation of a risk stratification system for patients
403 with syncope in the emergency department: the OESIL risk score. *Eur.Heart J* **2003**,
404 *24*, 811–819.
- 405 22. Sun, B.C.; Thiruganasambandamoorthy, V.; Cruz, J.D. Standardized reporting
406 guidelines for emergency department syncope risk-stratification research. *Acad*
407 *Emerg Med* **2012**, *19*, 694–702.
- 408 23. Solbiati, M.; Dipaola, F.; Villa, P.; Seghezzi, S.; Casagrande, I.; Rabajoli, F.; Fiorini,
409 E.; Porta, L.; Casazza, G.; Voza, A.; et al. Predictive Accuracy of
410 Electrocardiographic Monitoring of Patients With Syncope in the Emergency
411 Department: The SyMoNE Multicenter Study. *Acad. Emerg. Med.* **2019**, acem.13842.
- 412 24. Ungar, A.; Del Rosso, A.; Giada, F.; Bartoletti, A.; Furlan, R.; Quartieri, F.; Lagi, A.;
413 Morrione, A.; Mussi, C.; Lunati, M.; et al. Early and late outcome of treated patients
414 referred for syncope to emergency department: the EGSYS 2 follow-up study. *Eur.*
415 *Heart J.* **2010**, *31*, 2021–6.

- 416 25. Solbiati, M.; Bozzano, V.; Barbic, F.; Casazza, G.; Dipaola, F.; Quinn, J. V.; Reed,
417 M.J.; Sheldon, R.S.; Shen, W.-K.; Sun, B.C.; et al. Outcomes in syncope research: a
418 systematic review and critical appraisal. *Intern. Emerg. Med.* **2018**, *13*, 593–601.
- 419 26. Furlan, L.; Solbiati, M.; Pacetti, V.; Dipaola, F.; Meda, M.; Bonzi, M.; Fiorelli, E.;
420 Cernuschi, G.; Alberio, D.; Casazza, G.; et al. Diagnostic accuracy of ICD-9 code
421 780.2 for the identification of patients with syncope in the emergency department.
422 *Clin. Auton. Res.* **2018**.

423

424

Supporting information

425 **S1 Table. Example clinical cases with the probabilities predicted by attribute**
426 **matching and clinical judgement.** BP: blood pressure; HR: heart rate; ECG:
427 electrocardiogram; ED: Emergency Department; CI: Confidence Interval.